文献速递药疹与重症皮肤不良反应

皮肤苔藓样药物疹:一项评估人口学特征、临床特征及致病药物的叙述性综述

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-02-04

该叙述性综述检索MEDLINE 2000年1月至2021年1月文献,纳入163篇报告中的323例皮肤苔藓样药物疹病例。最常见致病药物为检查点抑制剂(136例,42.1%)、酪氨酸激酶抑制剂(39例,12.0%)和抗TNF-α单克隆抗体(13例,4.0%);平均潜伏期15.7周,停药后中位消退时间14.2周。作者认为该病诊断具有挑战性,仅26%病例需停用致病药物。

要点

  • 检查点抑制剂是最常见致病药物(136例,42.1%),其次为酪氨酸激酶抑制剂(39例,12.0%)和抗TNF-α单克隆抗体(13例,4.0%)。
  • 用药至皮疹出现平均潜伏期15.7周(范围0.1-208周),停药后中位消退时间14.2周(范围0.71-416周)。
  • 136例(42.1%)使用局部糖皮质激素,54例(16.7%)使用全身糖皮质激素;仅26%病例需停用致病药物。

核心结论

  • 作者认为,皮肤苔藓样药物疹虽罕见但诊断具有挑战性,多由检查点抑制剂、酪氨酸激酶抑制剂和生物制剂诱发。
  • 作者指出,治疗方式类似扁平苔藓,仅26%病例需停用致病药物,与其他类型药物不良反应相比比例较低,可能归因于继续用药时病情加重(如中毒性表皮坏死松解症)风险低且获益/风险比倾向于继续用药,这在肿瘤治疗中常见。

研究设计与样本

  • 叙述性综述,检索MEDLINE 2000年1月至2021年1月27日文献,关键词为「lichenoid drug rash」和「lichenoid drug eruption」。
  • 纳入标准为诊断为皮肤苔藓样药物疹且明确致病药物的病例,最终从163篇已发表病例报告和研究中识别323例。

主要发现

  • 患者平均年龄58.5岁(范围1个月至92岁),135例(41.8%)为女性。
  • 检查点抑制剂为最常报告致病药物(136例,42.1%),其次为酪氨酸激酶抑制剂(39例,12.0%)和抗TNF-α单克隆抗体(13例,4.0%)。
  • 用药至皮疹出现潜伏期为15.7周(范围0.1-208周),停药后中位消退时间为14.2周(范围0.71-416周)。
  • 136例(42.1%)接受局部糖皮质激素治疗,54例(16.7%)接受全身糖皮质激素治疗。
  • 仅26%病例需停用致病药物。

临床怎么用

  • 作者认为皮肤苔藓样药物疹的治疗方式类似扁平苔藓。
  • 作者指出仅26%病例需停用致病药物,比例低于其他类型药物不良反应,可能因继续用药时病情加重风险低且获益/风险比倾向于继续用药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cutaneous lichenoid drug eruptions (LDE) are adverse drug reactions (ADR) characterized by symmetric, erythematous, violaceous papules reminiscent but rarely fully characteristic of lichen planus (LP). We aimed to analyse the literature describing cases of LDE within the last 20 years to provide additional insight into culprit drugs, typical latency to onset of the eruption, the spectrum of clinical presentations, severity and management. A literature search was conducted in MEDLINE between January 2000 and 27 January 2021. The keywords 'lichenoid drug rash' and 'lichenoid drug eruption' were used. Cases were included if LDE diagnosis was made, and culprit drugs were identified. A total of 323 cases with LDE were identified from 163 published case reports and studies. The mean patient age was 58.5 years (1 month to 92 years), and 135 patients (41.8%) were female. Checkpoint inhibitors (CKI) were the most frequently reported culprit drugs (136 cases; 42.1%), followed by tyrosine kinase inhibitors (TKI) (39 cases; 12.0%) and anti-TNF-α-monoclonal antibodies (13 cases; 4.0%). The latency between initiation of the drug and manifestation was 15.7 weeks (range: 0.1-208 weeks). After discontinuing the culprit drug, the median time to resolution was 14.2 weeks (range: 0.71-416 weeks). One hundred thirty-six patients (42.1%) were treated with topical, and 54 patients (16.7%) with systemic glucocorticoids. Overall, we conclude that, albeit rare, LDE is challenging to diagnose ADR induced by mostly CKI, TKI, and biologics. Treatment modalities resemble that of lichen planus, and the culprit drugs had to be discontinued in only 26%, which is low compared with other types of adverse drug reactions. This is probably due to the low risk of aggravation (e.g. toxic epidermal necrolysis) if the drug is continued and the benefit/risk ratio favouring the drug, as is often the case in cancer therapy.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Maul JT, Guillet C, Oschmann A, et al. Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications. J Eur Acad Dermatol Venereol. 2023. PMID: 36652271. doi:10.1111/jdv.18879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。